ugli
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| ugli [2025/12/19 16:05] – sylvia | ugli [2025/12/19 16:05] (current) – sylvia | ||
|---|---|---|---|
| Line 81: | Line 81: | ||
| Important to note: **UGLI3 currently has a publication restriction**. the UGLI-consortium is currently preparing their manuscript describing the dataset and its primary analyses. Other manuscripts using UGLI3 data may not be submitted **before 31 December 2026**. | Important to note: **UGLI3 currently has a publication restriction**. the UGLI-consortium is currently preparing their manuscript describing the dataset and its primary analyses. Other manuscripts using UGLI3 data may not be submitted **before 31 December 2026**. | ||
| - | As of december 2025, data of 60,157 genotyped participants | + | As of december 2025, data of 60,157 genotyped participants |
| 63,553 participants were selected for UGLI 2+3 release and assessed using the pre mentioned array. All genotypes were included for QC screening, but the QC focussed on the the autosomes and chromosomes X for which there are N=615,682 and 22,346 markers available, respectively. A final set of 60,157 samples and 476,693 markers on autosomal and X chromosomes passed the QC steps described in the quality check rapport. | 63,553 participants were selected for UGLI 2+3 release and assessed using the pre mentioned array. All genotypes were included for QC screening, but the QC focussed on the the autosomes and chromosomes X for which there are N=615,682 and 22,346 markers available, respectively. A final set of 60,157 samples and 476,693 markers on autosomal and X chromosomes passed the QC steps described in the quality check rapport. | ||
ugli.txt · Last modified: by sylvia
